Gary Roubin Purchases 90,000 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) Director Gary Roubin acquired 90,000 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was purchased at an average cost of $1.18 per share, for a total transaction of $106,200.00. Following the completion of the purchase, the director directly owned 834,478 shares in the company, valued at $984,684.04. This trade represents a 12.09% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

InspireMD Price Performance

Shares of NSPR stock traded down $0.01 during mid-day trading on Friday, hitting $1.15. The stock had a trading volume of 188,622 shares, compared to its average volume of 174,055. InspireMD, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $2.93. The firm has a market cap of $53.93 million, a PE ratio of -1.53 and a beta of 0.82. The company’s 50-day simple moving average is $1.51 and its 200-day simple moving average is $1.75.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Maxim Group started coverage on shares of InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective for the company. Lake Street Capital set a $4.00 target price on InspireMD in a research note on Monday. Loop Capital set a $5.00 price target on InspireMD in a report on Tuesday, February 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of InspireMD in a report on Tuesday. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $4.50.

Institutional Trading of InspireMD

A number of institutional investors have recently added to or reduced their stakes in the stock. Creative Planning acquired a new position in InspireMD during the second quarter worth about $44,000. Raymond James Financial Inc. lifted its position in shares of InspireMD by 28.9% during the 2nd quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after acquiring an additional 10,000 shares during the period. Rosalind Advisors Inc. lifted its position in shares of InspireMD by 0.6% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock valued at $5,196,000 after acquiring an additional 14,109 shares during the period. Soleus Capital Management L.P. boosted its stake in shares of InspireMD by 99.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock worth $4,282,000 after acquiring an additional 940,831 shares in the last quarter. Finally, Courier Capital LLC boosted its stake in shares of InspireMD by 83.3% during the 3rd quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock worth $133,000 after acquiring an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.